• Explore /
  • Poster
  • / CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients (pts) with advanced or metastatic solid tumors.

CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients (pts) with advanced or metastatic solid tumors.

Abstract Poster

Authors

null

Ildefonso I Rodriguez Rivera

NEXT Oncology, San Antonio, TX

Ildefonso I Rodriguez Rivera , Navid Hafez , Anthony W. Tolcher , Patricia LoRusso , Sharon Wilks , Debu Tripathy , Michelle Gara , Paul Pearson , Arthur P. DeCillis , Funda Meric-Bernstam

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

New Targets and New Technologies (non-IO)

Clinical Trial Registration Number

NCT04902872

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3087)

DOI

10.1200/JCO.2023.41.16_suppl.3087

Abstract #

3087

Poster Bd #

285

Abstract Disclosures

Similar Posters

First Author: Charu Aggarwal

First Author: Keun-Wook Lee

First Author: Timothy Jay Price

First Author: Ying Liu